Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia / A. Cortelezzi, M.C. Pasquini, B. Sarina, G. Bertani, F. Grifoni, M. Colombi, G. Lambertenghi Deliliers. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 90:3(2005), pp. 410-412.
Titolo: | A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia |
Autori: | CORTELEZZI, AGOSTINO (Primo) PASQUINI, MARIA CRISTINA (Secondo) LAMBERTENGHI DELILIERS, GIORGIO (Ultimo) |
Parole Chiave: | Alemtuzumab; Autoimmune hemolytic anemia; B-CLL; Complete response; HBV; Overall response; Safety |
Settore Scientifico Disciplinare: | Settore MED/15 - Malattie del Sangue |
Data di pubblicazione: | 2005 |
Rivista: | |
URL: | http://www.haematologica.org/cgi/content/abstract/90/3/410 |
Tipologia: | Article (author) |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
410.full.pdf | Publisher's version/PDF | Open Access Visualizza/Apri |